SynthesisBMC cancer2016
Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis.
Synthesis in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Expression profiling of inhibitory immune checkpoints in colorectal cancer stem cells and their association with tumor immunity and immunotherapy biomarkers.Frontiers in immunology · 2026Article
- An Endolichenic Fungi-Derived Fatty Acid, cis-10-Nonadecenoic acid, Suppresses Colorectal Cancer Stemness.Biomolecules & therapeutics · 2025Article
- Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells.Molecular cancer research : MCR · 2025Article
- LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance.Cancer metastasis reviews · 2025Review
- Enhancing precision in colorectal cancer surgery: development of an LGR5-targeting RSPO1 peptide mimetic as a contrast agent for intraoperative fluorescence molecular imaging.Cell cycle (Georgetown, Tex.) · 2024Article
- Peristalsis-Associated Mechanotransduction Drives Malignant Progression of Colorectal Cancer.Cellular and molecular bioengineering · 2023Article
- The role of microvesicles as biomarkers in the screening of colorectal neoplasm.Cancer medicine · 2022Article
- Disruption of the crypt niche promotes outgrowth of mutated colorectal tumor stem cells.JCI insight · 2022Article
- LGR5, HES1 and ATOH1 in Young Rectal Cancer Patients in Egyptian.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Article
- Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact.Surgery today · 2020Review
- m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.Oncology reports · 2020Observational
- The Expression Analysis of Intestinal Cancer Stem Cell Marker Lgr5 in Colorectal Cancer Patients and the Correlation with Histopathological Markers.Journal of gastrointestinal cancer · 2020Article
- Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells.Frontiers in genetics · 2020Review
- The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication.Frontiers in cell and developmental biology · 2020Review
- Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.Theranostics · 2019Article
- Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 predicts poor prognosis in hepatocellular carcinoma.Saudi journal of biological sciences · 2018Article
- Logarithmic expansion of LGR5Cellular signalling · 2018Article
- Verrucarin J inhibits ovarian cancer and targets cancer stem cells.Oncotarget · 2017Article
- Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness.The Journal of biological chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLgr5 has recently been identified as a reliable biomarker of cancer stem cells (CSCs) in colorectal cancer (CRC); however, its prognostic value is still controversial.
methodsWe searched PubMed, Web of Science, and Wanfang databases with identical strategies to retrieve articles. We evaluated the impact of Lgr5 expression on survival of CRC patients through meta-analysis.
resultsA total of 12 studies comprising 2600 patients revealed that Lgr5 overexpression was negatively associated with overall survival (OS) (HR = 1.73, 95% CI: 1.28-2.33; P = 0.00) and disease free survival (DFS) (HR = 2.89, 95% CI: 1.89-4.44; P = 0.000) in CRC patients. Subgroup analysis suggested that Lgr5 overexpression was significantly associated with worse OS in subgroups with IHC as the method of Lgr5 assessment (HR = 2.01, 95% CI: 1.39-2.89; P = 0.001), patients from Asia (HR = 1.81, 95% CI: 1.27-2.58; P = 0.000), and NOS scores greater than 6 (HR = 2.12, 95% CI: 1.41-3.19; P = 0.000). Furthermore, sensitivity analysis showed that the estimated HR ranged from 1.6 to 1.86 upon excluding one study sequentially from each analysis. In addition, Lgr5 overexpression was significantly associated with deep invasion of CRC (OR = 0.39, 95% CI: 0.17-0.87; P = 0.002), lymphnode metastasis (OR = 0.45, 95% CI: 0.26-0.76; P = 0.003), distant metastasis (OR = 0.37, 95% CI: 0.22-0.62; P = 0.000), and AJCC stage (OR = 0.35, 95% CI: 0.15-0.78; P = 0.01). However, Lgr5 overexpression was not correlated with tumor grade (OR = 0.75 95% CI: 0.37-1.54; P = 0.433).
conclusionsThis study shows that Lgr5 can be a valuable and reliable prognostic factor of colorectal cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.